A general limitation in gene delivery is the cellular uptake in lager animals including humans. Several approaches have been tested including liposomes, micro-needles, in vivo electro-transfer, ballistic delivery, and needle-free delivery. All these techniques have individual limitations. One approach reproducibly delivering genetic material in muscle tissue in nonhuman primates is hydrodynamic injection, a forced injection of a volume equaling the volume of the tissue to be transfected thereby causing an increased local pressure resulting in an improved uptake of genetic material. We transferred the principle of hydrodynamic injection to a device, where a small injection volume can be delivered to a targeted tissue volume, termed in vivo intracellular injection (IVIN). The device is based on needle(s) with apertures along the needle shafts, where multiple needles can fix the tissue volume to be transfected. The apertures direct the injection from a central needle outward or inward to the centroid of a geometric arrangement thereby targeting the tissue to be transfected. With a controlled force, this results in a targeted injection with increased transfection efficiency. We here show that the IVIN technology reproducibly improved plasmid uptake and expression and the immunogenicity. The IVIN technology can be generally applied to a targeted delivery of genetic materials.
INTRODUCTION
DNA, and now also RNA, vaccines are relatively simple to produce and can streamline and simplify a vaccine production line. A major limitation of DNA/RNA vaccines is the poor uptake in cells of larger animals. This may be overcome by the use of various more or less advanced delivery techniques that can be extended for human use. [1] [2] [3] [4] In smaller animals, such as mice and smolt (young salmon or rainbow trout), the genetic material is taken up surprisingly effective. 5, 6 One reason for this is most likely the disproportionally large volume that is used for the injection, where fish weighing around 1-2 g are injected with DNA in a volume of 50 µl. 7 Also, a 50 µl volume is commonly used to inject genetic material into the tibialis cranialis muscle of mice, which is almost the same volume as the muscle itself. Injection of the same volume in the mouse quadriceps muscle is significantly less effective. Hence, there is most likely a transiently increased hydrostatic pressure in the tissue that improves the uptake of the genetic material. A transiently increased hydrostatic pressure has in fact been applied to gene transfer and has been termed a hydrodynamic injection. This has been effectively applied to in vivo transfection of mouse livers 8, 9 and muscle tissue in nonhuman primates. 6 The principle is that a tissue is overloaded by a forced injection with a volume that equals the volume of the tissue to be transfected. E.g., the example of the nonhuman primate would correspond to an injection of around 100 ml into a limb. Such a volume is of course not acceptable for most future treatments where a small local uptake of the genetic material is desired, as in vaccinations. Thus, it would be of interest to apply the hydrodynamic injection technology with much smaller injection volumes in larger animals including humans. In addition, to make the use of gene therapy and genetic vaccinations more available, the device should be as simple as possible, independent of the physical capabilities of the operator, and preferentially not need any compressed gas, electromechanical drives, or advanced apparatus, such as in vivo electrotransfer or a ballistic delivery device such as the gene gun.
Herein, we describe the use of a new delivery device, termed in vivo intracellular injection (IVIN) device, which delivers a small injection volume, by the use of a compression spring, to a targeted tissue volume resulting in an improved uptake and expression of the vaccine antigen.
RESULTS

Inventing the IVIN device
We started designing a device that could use the advantages of uptake of genetic material mediated by the targeted controlled force injection but that could be used for injection of volumes of 1 ml or less. We envisioned that if one could isolate a tissue volume and overload the same tissue with a solution containing genetic material, this would correspond to a hydrodynamic injection. This could be achieved using one or more needles where the apertures are located along the needle shaft (Figure 1a-c) . With multiple needles arranged in a circular pitch, and possibly with a central needle, so that the apertures oppose each other, an effective overloading of the tissue should be achieved. The needles located along the circle will fix the tissue that is targeted so that the tissue does not flex during the injection (Figure 1d ). To avoid bending of the needles during insertion, the needles were designed with trocar tips (Figure 1b) . A number of different needle configurations were explored (Figure 1d ), in order to understand what impact this would have on vaccine take up. It was important that these different hub designs should be able to connect to commercially available syringes to reduce development risks and provide a more straightforward route to a commercial product. Additional factors that may affect the efficiency of the uptake of the genetic material are the spacing between the needles, the number of apertures on the shafts, the size of the apertures, and the injection force. In order to control the injection force and provide a consistent tissue-overloading effect that would not be limited by the capabilities of the device operator, we designed spring-loaded injection devices. One for i.m. delivery in larger animals such as rabbits and pigs with a larger spring and greater spacing between needles ( Figure 1e ) and a smaller for i.m. delivery in mice or skin delivery in larger animals ( Figure 1f ).
Factors influencing transfection efficiency and inflammation in vivo using the IVIN device To identify the key parameters that determine the efficiency of the IVIN technology, we first performed gene transfer experiments in rabbits, which we here consider as a larger animal as the muscle sizes better resemble those of humans. The parameters tested included the size of apertures (50 or 100 µm), the injection force (50-225 N), the distance between needles (3 or 6 mm), and the needle configuration (O-, X-, or Y-shaped pattern).
These parameters were tested with the readout being the ability to transfect rabbit tibialis anterior muscles in vivo and to cause a local inflammation using a plasmid expressing the hepatitis C virus nonstructural (NS) 3/4A proteins, administered as a 0.3 ml injection with 3 mg/ml of DNA. A general pattern was that both transfection and inflammation seemed to appear along the needle tracks ( Figure 1g ). Subgroups were grouped into larger groups to allow for statistical analysis. For example, in the two groups comparing the apertures, subgroups include different injections forces, different needle distances, and different needle configuration. The purpose of this type of comparison was to find parameters that could override the influence of the subgroups.
With respect to these parameters, we first found that the size of the apertures seemed to affect in vivo transfection efficiency (Figure 2a ). It is likely that an increased area of the apertures drastically reduces the dynamic force of the injection fluid. Simply considering the issue as a matter of mass flow, apertures of half the diameter (0.05 mm as opposed to 0.1 mm) will have one quarter of the cross-sectional area and so to deliver the same volume of vaccine in the same amount of time the vaccine will have to be travelling four times as quickly as it leaves the needle aperture. The model ignores the effect of tissue resistance and pressure drop across each of the apertures, but the fundamental approach is sound and has been supported with high-speed video analysis of the two aperture sizes at different injection pressures. This behavior is further supported by the subgroup analysis where injection at a lower force was less effective with larger apertures (Figure 2c ), whereas at a higher injection force the aperture size was less important (Figure 2d) . Thus, the injection force should not be too low. There is a practical upper limit to the injection force as using too high a force leads to the vaccine solution leaking behind the plunger bung in the syringe barrel. injection forces used by the ADU. The different aperture diameter and its effect using (c) low and (d) high injection force. Influence of the distance between the (e) needles and (f) the different needle configurations. The statistical difference was determined using Mann-Whitney U-test (P < 0.05; P < 0.001). NS, not significant, indicates no statistical difference. ADU, adjustable delivery unit; IVIN, in vivo intracellular injection. However, the individual role of injection force is most likely confounded by the two aperture diameters (Figure 2b ). There was an influence also from the distance between the needles (Figure 2e ). However, it is possible that this could be due to the fact that a larger spacing reduces the probability of two needle tracks ending up on the same histological section. A limiting factor is that the groups are too small to allow for multiple parameters at the same time. We also analyzed the influence of these parameters on the degree of local inflammation caused by the injection. The major factor that influenced the extent of inflammation at the injection site was the aperture diameter, with an increased area of inflammation seen with larger apertures (Figure 3) . Thus, the size of the apertures had somewhat contradictory effects with respect to transfection and inflammation. As transfection efficiency is the key parameter, we delivered DNA using a four-needle array in a Y-shaped configuration with 50 µm apertures in following experiments (Figure 1g ). IVIN delivery improves immunogenicity and can effectively be combined with in vivo electrotransfer in mice Form the previous experiments, it was clear that the IVIN technology was superior in gene transfer in rabbits as compared to a regular needle injection. We now wanted to investigate if this is translated into an improved immunogenicity and if the performance could be further improved. We now transferred our experience from the rabbit to mice with a smaller spring-loaded hand-held IVIN device designed for mice. We tested both different injection forces and the possibility to combine the IVIN with in vivo electrotransfer (ET). The readouts were inflammation, transfection, and immunogenicity using different plasmids.
We first evaluated two different pulse patterns for the in vivo ET with a regular injection needle. One based on our previously used with two 60 ms pulses of 246 V/cm and the other with a short high-voltage pulse (1 ms 600 V/cm) followed by a long low-voltage pulse (400 ms 60 V/cm). The high-low pulse pattern induced a stronger T-cell response without causing increased tissue damage ( Figure 4 ). Consistent with our previous experience, in vivo ET enhanced plasmid uptake, inflammation, and antigen expression ( Figure 4) .
As most reagents for immunological characterization are available for mice, we further evaluated the IVIN in mice. We first evaluated the possibility of combining the IVIN technology using different injection forces ranging from 9 to 20 N (a 10-fold scale down from the larger device injecting a 10 times larger volume) with in vivo ET. This showed that IVIN could be effectively combined with in vivo ET ( Figure 5 ). Also, regardless of the injection forces used, did the IVIN consistently induce stronger immune responses than a regular needle in mice when combined with in vivo ET ( Figure 5 ), supporting the data from the rabbits (Figures 1-3) . NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml Medium ConA (old) 2 µg/ml ConA (old) 1 µg/ml ConA (old) 0.5 µg/ml ConA (old) 0.1 µg/ml 50 µg coNS3/4A no in vivo ET NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml Medium ConA (old) 2 µg/ml ConA (old) 1 µg/ml ConA (old) 0.5 µg/ml ConA (old) 0.1 µg/ml Nonimmunized NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml Medium ConA (old) 2 µg/ml ConA (old) 1 µg/ml ConA (old) 0. To better understand the mechanism for the improved immunogenicity in mice, we also analyzed the in vivo transfection efficiency determined as NS3-expression ( Figure 6a ). This confirmed our observations regarding the IVIN from the rabbit, with higher transfection efficiencies using the IVIN as compared to a regular needle and further improved transfection when IVIN was combined with in vivo ET ( Figure 6a ). Importantly, we could show that the in vivo transfection efficiency was paralleled by an increased immunogenicity determined by both the number of IFNγ-producing cells and the total number of epitope-specific cytotoxic T lymphocytes (CTLs) (Figure 6b ,c). Taken together, these data clearly confirmed that the IVIN technology had a superior transfection efficiency resulting in a superior immunogenicity, as compared to a regular needle ( Figures 5 and 6 ).
We further dissected the combination of the IVIN device with a 150 N injection force, with different in vivo ET pulses to deliver a combination of a vaccine plasmid and an adjuvant plasmid-expressing IL-12 ( Figure 7 ). The combination of the high and low pulse was superior to either pulse alone in priming HCVspecific T cells ( Figure 7 ). In particular, the responses to the T-helper epitope (E13K; Figure 7a ,b) and the priming of IL-2-producing T cells were greatly improved by the combination of the IVIN and in vivo ET (Figure 7b ). Thus, this confirms that the combination of the IVIN and in vivo ET not only improves transfection efficiencies but also the immunogenicity.
Immunogenicity of the IVIN combined with in vivo ET in pigs As a final test of the IVIN technology, we wanted to evaluate immunogenicity in a larger animal closer to the size of a human. We here used pigs, which are large (10-25 kg) and for which there is a reliable IFNγ-Elispot assays as readout of immunogenicity. In addition, pig Figure 5 Evaluation of different injection forces for optimal immune priming of T cells. Groups of five C57BL/6J mice were immunized once with 5 μg of C2.2-pVAX1 plasmid in a volume of 30 μl by i.m. immunization using the IVIN technology and three different injection forces (75, 150, and 223 N) followed by in vivo ET with a pulse pattern of 1 ms 600 V/cm × 400 ms 60 V/cm. Two weeks after immunization, the mice were sacrificed and splenocytes harvested for determination of T-cell responses. A comparison of the number of IFN-γ spot-forming cells (SFCs) by enzyme-linked immunospot (ELISpot) assay after stimulation with a NS3-cytotoxic T lymphocyte peptide, a Th peptide (E13K), or a recombinant NS3 (rNS3) protein between the groups of mice immunized using different injection forces. Results are given as the mean SFCs/10 6 (+SD) with a cutoff set at 50 SFCs/10 6 splenocytes. The statistical differences shown indicate a group that is significantly different from the group immunized using regular 27G needle (i.m./ET) (*P < 0.05 and **P < 0.01, and ***P < 0.001, by comparing area under the curve (AUC) and analysis of variance (ANOVA)). ET, electrotransfer; IVIN, in vivo intracellular injection. NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml E13K 0.01 µg/ml E13K 0.001 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml rNS3 0.8 µg/ml rNS3 0.16 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml Medium ConA 2 µg/ml ConA 1 µg/ml ConA 0.5 µg/ml ConA 0.1 µg/ml 5 µg C2.2 IVIN 223 N/ET NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml E13K 0.01 µg/ml E13K 0.001 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml rNS3 0.8 µg/ml rNS3 0.16 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml Medium ConA 2 µg/ml ConA 1 µg/ml ConA 0.5 µg/ml ConA 0.1 µg/ml 5 µg C2.2IVIN 75 N/ET NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml E13K 0.01 µg/ml E13K 0.001 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml rNS3 0.8 µg/ml rNS3 0.16 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml skin is somewhat similar to human skin and thus suited to also test the IVIN technology for skin delivery. We used the large IVIN for i.m. delivery and the small IVIN for skin delivery. A total of four pigs were immunized with different combinations of the coNS3/4A vaccine. We found that already a single injection effectively primed detectable NS3-specific T cells in pigs using both i.m. or skin delivery (Figure 8 ). These responses were improved in a skin-prime and skin-boost regimen ( Figure 8 ) and also to some extent in a i.m. NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml E13K 0.01 µg/ml E13K 0.001 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml rNS3 0.8 µg/ml rNS3 0.16 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml E13K 0.01 µg/ml E13K 0.001 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml rNS3 0.8 µg/ml rNS3 0.16 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml Medium ConA 2 µg/ml ConA 1 µg/ml ConA 0.5 µg/ml ConA 0.1 µg/ml 5 µg C2.2 IVIN 223 N/ET NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml E13K 0.01 µg/ml E13K 0.001 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml rNS3 0.8 µg/ml rNS3 0.16 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml Medium ConA 2 µg/ml ConA 1 µg/ml ConA 0.5 µg/ml ConA 0.1 µg/ml 5 µg C2.2 IVIN 223 N NS3 CTL 0.25 µg/ml NS3 CTL 0.025 µg/ml NS3 CTL 0.0025 µg/ml NS3 CTL 0.00025 µg/ml NS3 CTL 0.000025 µg/ml NS3 CTL 0.0000025 µg/ml NS3 CTL 0.00000025 µg/ml NS3 CTL 0.000000025 µg/ml E13K 10 µg/ml E13K 1 µg/ml E13K 0.1 µg/ml E13K 0.01 µg/ml E13K 0.001 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml rNS3 0.8 µg/ml rNS3 0.16 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml responses also in larger animals. It is important to note that the vaccinations were given as a two-step procedure, with a first injection of the DNA using the IVIN followed by the ET using a separate probe manually inserted at the injection site. If this is combined into a single device providing both the targeted controlled force injection and the in vivo ET, the results may be further improved.
DISCUSSION
The major limitation with DNA and RNA vaccines is the insufficient uptake of the genetic material into the cells of larger animals and humans. It is well known that plasmid DNA is poorly taken up when injected into humans using a standard hypodermic needle due to the injection of a small volume in a large muscle tissue. 10 The DNA will stay in the extracellular space and become degraded or excreted. Several devices have been developed with the aim at solving this problem. However, even if improvements have been made, so far no delivery devices have shown to be simple enough to enable effective human DNA/RNA vaccines. Contrary, in a 20 g mouse, the injected volume often equals the size of the muscle, whereby an overloading of the tissue causes a hydrostatic pressure in the tissue forcing the muscle cells to take up the DNA. Along the same lines, it has been shown that in large animals, such as monkeys, the isolation of muscles in the underarm by a tourniquet followed by overloading the tissue by an injection of 100 ml of plasmid-containing solution results in DNA uptake. 10 Therefore, it would be of interest if one could isolate a smaller area of the muscle and overload it to cause the hydrostatic pressure only in that region. The aim of this study was to develop a simple injection device for a targeted controlled force delivery of genetic material into an isolated area of muscle or skin. To achieve such conditions in a large animal using a small injection volume, we aligned multiple needles on a circular pitch with apertures laser cut on the side of the shafts and with sharp trocar ends. In this way, the solution is injected centrally into the muscle volume locked by the surrounding needles. Hereby, we effectively isolate a given volume of tissue that will become overloaded with the injected vaccine to promote a localized uptake of genetic material. Initial experiments in rabbits supported the theory in practice resulting in an improved antigen expression in vivo. However, through mathematical modeling, we realized the importance of controlling the injection speed. We therefore developed a spring-loaded delivery device that delivers the injection at a controlled force. Next, we evaluated key parameters such as size of apertures, the injection force, the distance between needles, and the needle configuration that determine the transfection efficiency and the inflammation caused by the IVIN technology. The size of the apertures affected in vivo transfection efficacy since smaller (50 μm) apertures seemed to have a higher transfection efficacy than the larger (100 μm) apertures. However, at higher injection forces (<100 N in the larger device), no significant difference was observed between the different aperture sizes with respect to transfection efficacy or inflammation. Based on the overall results, we decided to deliver DNA using a four-needle array in a Y-shaped configuration with 50 µm apertures. To perform more detailed studies on the IVIN technology, we transferred our experience from the rabbits to mice using a smaller spring-loaded hand-held IVIN specially designed for mice. This allowed us to evaluate not only transfection and inflammation but also more importantly the effect on immunogenicity. Furthermore, we could now test the role of different injection forces and the possibility to combine IVIN with in vivo ET. We have previously shown that in vivo ET greatly improves transfection efficacy and immunogenicity of DNA vaccines. [11] [12] [13] We first evaluated whether different pulse pattern for the in vivo ET had an impact on the transfection efficacy and immune activation. A high-low pulse combination pattern induced a high transfection rate, influx of CD3+ cells, and a strong T-cell response. This may be explained by the fact that the higher pulse increases the permeability of the cell membranes, and that the lower pulse promotes electrophoretic transfer of the plasmids inside the cells.
14 Next, we evaluated the combination of IVIN technology and in vivo ET. The IVIN was consistently better at inducing immune reposes as compared to a regular needle. This suggested to us that the addition of in vivo ET might even further improve the performance of the IVIN. To test the importance of both IVIN and in vivo ET, we determined the HCV NS3-protein expression after injection with and without IVIN and in vivo ET. This showed that both in vivo ET and IVIN had effects on the transfection efficacy when used alone; however, the combination of these was superior. We further tested the combination of the IVIN device with a 150 N injection force with different in vivo ET pulses to deliver a combination of plasmids. The combination of a high and a low pulse was superior to either pulse alone in priming HCV-specific T cells reaching IFN-γ responses up to 4,000 spot-forming cells (SFCs)/10 6 after a single immunization of only 5 μg vaccine. This is consistent with previous observations where different pulses were combined.
14 Thus, the combination of IVIN and in vivo ET was highly effective in mice and should therefore be further explored in larger animals. As a first set of experiments, we used pigs since they resemble humans in size of muscle tissue and share similarities with human skin. Using a two-step administration procedure, with a first IVIN injection followed by in vivo ET, we found that both i.m. and skin immunization primed HCV-specific IFN-γ responses supporting that the combined IVIN technology works in larger animals. However, the major advantage of the IVIN technology will be when the injection needles also acts a electrodes for the ET, since then the whole procedure is done in a single step. Such a device is currently under development.
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MATERIALS AND METHODS Animals
Inbred female C57BL/6J (H-2 b ) mice were housed at Karolinska Institutet, Division of Comparative Medicine, Clinical Research Center, Karolinska University Hospital, Huddinge, Sweden. The mice were purchased from approved vendors (Charles River Laboratories, Sulzfeld, Germany and the Jackson Laboratory, Bar Harbor, ME). The mice were caged at 5-10 mice per cage and fed with a commercial diet (RM3 (p) PL IRR diet; Special Diet Service) with free access to food and water. All mice were 6-10 weeks of age at the start of the experiment. New Zealand White (NZW) rabbits weighing 2.5-3.5 kg, and landrace pigs of 6 weeks of age, were purchased from commercial vendors and were kept at Adlego Biomedical AB, Astrid Fagraeus Laboratory, Karolinska Institutet, Solna, Sweden. All animal studies were approved by the Ethical Committee for Animal Research.
Plasmid DNA
The codon-optimized (co) NS3/4A-pVAX1 genotype 1a plasmid (GenBank accession number: AR820945.1; http://www.nbci.nlm.nih.gov/genbank) has been described previously. 15 In addition, a codon-optimized fusion construct of NS3/4A and stork HBcAg (coStork-HBcAg) C2.2 has been described previously (Levander et al., manuscript submitted). The C2.2 (GenBank accession number: GZ869906.1) contain an NS3-NS4A cleavage site between NS3 and NS4A and an NS4A-NS4B cleavage site between NS4A and stork-HBcAg. NS3, NS4A, and stork-HBcAg are separated by NS3/4A proteolytic cleavage, and the coStork-HBcAg contain modifications consisting of the introduction of three NS3-NS4A cleavage sites in the coStork-HBcAg gene sequence, allowing the expressed NS3/4A protease to cleave the modified Stork-HBcAg into four parts (Stork-HBcAg: aa 1-66, aa 67-132, aa 133-198, and aa 199-264). Mouse IL-12 (pORF-mIL-12) was purchased from InvivoGen (San Diego, CA). Plasmids were grown in competent TOP10 E. coli (Life Technologies, Carlsbad, CA) and purified using Qiagen EndoFree Plasmid Purification Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). Plasmid DNA concentration was determined spectrophotometrically, and the purified DNA was dissolved in sterile phosphate-buffered saline at concentrations of 2 mg/ml. Restriction enzyme digest and sequencing (Eurofins MWG Operon, Ebersberg, Germany) was performed to control the size of the insert and to ensure correct nucleotide sequence. Plasmid constructs were analyzed for protein expression and proteolytic activity by an in vitro transcription and translation assay (Promega, Madison, WI) and by transient transfection and western blot analysis as described elsewhere (Levander et al., manuscript submitted). 15, 16 Peptides and proteins 1372-1386, gt1a) ). 18 As control peptides, we used ovalbumin: SIINFEKL (OVA 257-264, CTL-epitope) and ISQAVHAAHAEINEAGR (OVA 323-339, Th-epitope) synthesized by automated peptide synthesis as described previously (ChronTech Pharma AB, Huddinge, Sweden). 19 Recombinant HCV NS3 protein gt1a (aa 1207-1612) were produced in E. coli and purified as described. 20 Chicken egg albumin (OVA) and Concanavalin A (ConA) were purchased from Sigma Aldrich (St Louis, MO).
IVIN device for delivery of DNA vaccine
The IVIN device is a multineedle injection device where the sharp end of the needles has been sealed and several 6 (+SD) with a cutoff set at 100 SFCs/10 6 peripheral blood mononuclear cells.
NS3 CTL Pool-1 10 µg/ml NS3 CTL Pool-1 1 µg/ml NS3 CTL Pool-2 10 µg/ml NS3 CTL Pool-2 1 µg/ml NS3 CTL Pool-3 10 µg/ml NS3 CTL Pool-3 1 µg/ml NS3 CTL Pool-4 10 µg/ml NS3 CTL Pool-4 1 µg/ml NS3 CTL Pool-5 10 µg/ml NS3 CTL Pool-5 1 µg/ml NS3 CTL Pool-6 10 µg/ml NS3 CTL Pool-6 1 µg/ml NS3 CTL Pool-7 10 µg/ml NS3 CTL Pool-7 1 µg/ml NS3 CTL Pool-8 10 µg/ml NS3 CTL Pool-8 1 µg/ml NS3 CTL Pool-9 10 µg/ml NS3 CTL Pool-9 1 µg/ml NS3 CTL Pool-10 10 µg/ml NS3 CTL Pool-10 1 µg/ml NS3 CTL Pool-11 10 µg/ml NS3 CTL Pool-11 1 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml NS3 CTL Pool-1 10 µg/ml NS3 CTL Pool-1 1 µg/ml NS3 CTL Pool-2 10 µg/ml NS3 CTL Pool-2 1 µg/ml NS3 CTL Pool-3 10 µg/ml NS3 CTL Pool-3 1 µg/ml NS3 CTL Pool-4 10 µg/ml NS3 CTL Pool-4 1 µg/ml NS3 CTL Pool-5 10 µg/ml NS3 CTL Pool-5 1 µg/ml NS3 CTL Pool-6 10 µg/ml NS3 CTL Pool-6 1 µg/ml NS3 CTL Pool-7 10 µg/ml NS3 CTL Pool-7 1 µg/ml NS3 CTL Pool-8 10 µg/ml NS3 CTL Pool-8 1 µg/ml NS3 CTL Pool-9 10 µg/ml NS3 CTL Pool-9 1 µg/ml NS3 CTL Pool-10 10 µg/ml NS3 CTL Pool-10 1 µg/ml NS3 CTL Pool-11 10 µg/ml NS3 CTL Pool-11 1 µg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml Medium Medium
ConA 2 µg/ml ConA 1 µg/ml Nonimmunized NS3 CTL Pool-1 10 µg/ml NS3 CTL Pool-1 1 µg/ml NS3 CTL Pool-2 10 µg/ml NS3 CTL Pool-2 1 µg/ml NS3 CTL Pool-3 10 µg/ml NS3 CTL Pool-3 1 µg/ml NS3 CTL Pool-4 10 µg/ml NS3 CTL Pool-4 1 µg/ml NS3 CTL Pool-5 10 µg/ml NS3 CTL Pool-5 1 µg/ml NS3 CTL Pool-6 10 µg/ml NS3 CTL Pool-6 1 µg/ml NS3 CTL Pool-7 10 µg/ml NS3 CTL Pool-7 1 µg/ml NS3 CTL Pool-8 10 µg/ml NS3 CTL Pool-8 1 µg/ml NS3 CTL Pool-9 10 µg/ml NS3 CTL Pool-9 1 µg/ml NS3 CTL Pool-10 10 µg/ml NS3 CTL Pool-10 1 µg/ml NS3 CTL Pool-11 10 µg/ml NS3 CTL Pool-11 1 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml Medium Medium
ConA 2 µg/ml ConA 1 µg/ml NS3 CTL Pool-1 10 µg/ml NS3 CTL Pool-1 1 µg/ml NS3 CTL Pool-2 10 µg/ml NS3 CTL Pool-2 1 µg/ml NS3 CTL Pool-3 10 µg/ml NS3 CTL Pool-3 1 µg/ml NS3 CTL Pool-4 10 µg/ml NS3 CTL Pool-4 1 µg/ml NS3 CTL Pool-5 10 µg/ml NS3 CTL Pool-5 1 µg/ml NS3 CTL Pool-6 10 µg/ml NS3 CTL Pool-6 1 µg/ml NS3 CTL Pool-7 10 µg/ml NS3 CTL Pool-7 1 µg/ml NS3 CTL Pool-8 10 µg/ml NS3 CTL Pool-8 1 µg/ml NS3 CTL Pool-9 10 µg/ml NS3 CTL Pool-9 1 µg/ml NS3 CTL Pool-10 10 µg/ml NS3 CTL Pool-10 1 µg/ml NS3 CTL Pool-11 10 µg/ml NS3 CTL Pool-11 1 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml Medium Medium
ConA 2 µg/ml ConA 1 µg/ml 2 × 300 µg coNS3/4A muscle IVIN 150 N/ET skin IVIN 223 N/ET 2 × 300 µg coNS3/4A skin IVIN 223 N/ET 1 × 300 µg coNS3/4A skin IVIN 223 N/ET NS3 CTL Pool-1 10 µg/ml NS3 CTL Pool-1 1 µg/ml NS3 CTL Pool-2 10 µg/ml NS3 CTL Pool-2 1 µg/ml NS3 CTL Pool-3 10 µg/ml NS3 CTL Pool-3 1 µg/ml NS3 CTL Pool-4 10 µg/ml NS3 CTL Pool-4 1 µg/ml NS3 CTL Pool-5 10 µg/ml NS3 CTL Pool-5 1 µg/ml NS3 CTL Pool-6 10 µg/ml NS3 CTL Pool-6 1 µg/ml NS3 CTL Pool-7 10 µg/ml NS3 CTL Pool-7 1 µg/ml NS3 CTL Pool-8 10 µg/ml NS3 CTL Pool-8 1 µg/ml NS3 CTL Pool-9 10 µg/ml NS3 CTL Pool-9 1 µg/ml NS3 CTL Pool-10 10 µg/ml NS3 CTL Pool-10 1 µg/ml NS3 CTL Pool-11 10 µg/ml NS3 CTL Pool-11 1 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0.4 mg/ml OVA CTL 10 µg/ml OVA Th 10 µg/ml OVA protein 10 µg/ml !Medium g/ml ConA 2 µg/ml ConA 1 µg/ml Nonimmunized NS3 CTL Pool-1 10 µg/ml NS3 CTL Pool-1 1 µg/ml NS3 CTL Pool-2 10 µg/ml NS3 CTL Pool-2 1 µg/ml NS3 CTL Pool-3 10 µg/ml NS3 CTL Pool-3 1 µg/ml NS3 CTL Pool-4 10 µg/ml NS3 CTL Pool-4 1 µg/ml NS3 CTL Pool-5 10 µg/ml NS3 CTL Pool-5 1 µg/ml NS3 CTL Pool-6 10 µg/ml NS3 CTL Pool-6 1 µg/ml NS3 CTL Pool-7 10 µg/ml NS3 CTL Pool-7 1 µg/ml NS3 CTL Pool-8 10 µg/ml NS3 CTL Pool-8 1 µg/ml NS3 CTL Pool-9 10 µg/ml NS3 CTL Pool-9 1 µg/ml NS3 CTL Pool-10 10 µg/ml NS3 CTL Pool-10 1 µg/ml NS3 CTL Pool-11 10 µg/ml NS3 CTL Pool-11 1 µg/ml rNS3 10 µg/ml rNS3 2 µg/ml rNS3 0. (Figure 1d ) shaped formation. The holes were arranged to either project toward a central point or straight to the closest neighboring needle. For rabbit and pig studies, the needles were made with 27G (O/D 0.413 mm) surgical tubing, compliant with ISO 9626. Once the holes were cut, a short length of 27G solid rod was laser welded to the end of the tube (to close the distal end), and a three facet trocar was cut into this rod to assist in penetrating the skin without causing the needle to deflect, upsetting the alignment between the needles. The needles were then welded into stainless steel hubs, and the joints were tested to confirm that there were no leaks from the joints or welds. Each needle was inspected with a microscope and subject to high-speed video analysis to ensure a good flow could be achieved through each of the apertures. The hub was then built into an assembly with a threaded Luer Lock fitting to allow it to be mounted to a standard Luer Lock syringe. It was necessary to use a Luer Lock (rather than a Luer slip) due to the high pressure generated in the delivery system. The hub was made by XL Precision Technologies (Stockton on Tees, UK). XL Precision also provided the needles for the mouse studies; these needles were made in the same manner as the larger needles but were manufactured in 30G (O/D 0.311 mm) surgical tubing. The smaller 30G needles with their thinner section presented significant challenges for laser welding. The injection is a forced injection of 30-300 μl plasmid DNA solution. To evaluate different injection forces and to standardize the injection, a spring-loaded adjustable delivery unit has been developed for both larger animals and mice. Each of the adjustable delivery unit were designed in 3D using SolidWorks CAD software and were manufactured from machined stainless steel with sliding components manufactured in brass. The injection force was adjusted by modifying the compression on a coil spring; the force was verified using a tensile testing system and then clearly marked on each of the devices. The adjustable delivery units were manufactured by Gemini Prototyping (Worminghall, UK). The systems were designed as an investigative platform and so had a lot of flexibility to adjust loads and travel in order to establish an optimum delivery profile. To determine the most effective conditions for delivery of genetic material into muscles, the following parameters were evaluated in vitro and by injection in rabbit muscles: hole size (0.1, 0.05 mm), distance between needles 3 or 6 mm, configuration of the needles (O, X, or Y), number of apertures (48-144), and the injection force (50-150 N) (Figure 1a-f ) . The complete IVIN device was designed and assembled by Team Consulting (Cambridge, UK).
Immunization protocol
Rabbits (NZW) were immunized i.m. into the tibialis anterior muscles once with 0.9 mg DNA in a volume of 300 µl using a regular needle or the IVIN device. ET using the Cliniporator 2 device (IGEA, Carpi, Italy) of the injected area was applied immediately after the delivery of the DNA. Three days after DNA injection, the rabbits were sacrificed, and the injected muscle was collected for immunohistochemical analysis.
In landrace pigs, both i.m. and skin delivery was evaluated in combination with ET using the Cliniporator 2 device. A volume of 30 µl was used for the IVIN skin injections. The holes are located at a depth of 2-3 mm, thus targeting both the epidermis and the dermis. A total of six immunizations (0.5 mg/ injection) on the spine of the pigs were performed with 1 cm distance between injections. The skin was thereafter electrotransferred by 0.1 ms 1,000 V/cm + 200 ms 100 V/cm (1,000 ms between pulses). Intramuscular immunizations were performed using 0.3 mg DNA in 0.3 ml solution followed by an ET protocol of 0.1 ms 600 V/cm + 200 ms 60 V/cm (1,000 ms between pulses). The pigs were boosted 2 weeks after the initial immunization, and immune responses were determined by enzyme-linked immunospot (ELISpot) assay using peripheral blood mononuclear cells isolated 2 weeks after the first and second immunization.
Groups of 5-10 (mice/group) of female C57BL/6J (wt) mice were immunized i.m. in the tibialis cranialis muscle once with doses of 50, 20, or 5 μg plasmid DNA (e.g., coNS3/4A-pVAX1 or C2.2-pVAX1-pVAX1) alone or in combination with 5 μg mIL-12-pORF1 12 in a volume of 30 μl using the IVIN or regular needle injection. Immediately following administration of the plasmid DNA, tibialis cranialis muscles were subsequently electrotransferred using the Cliniporator 2 device (IGEA) with two 60 ms 246 V/cm pulses or 1 ms 600 V/cm pulse followed by a 400 ms 60 V/cm pulse pattern. For mice, the analysis of HCV NS3/4A-specific immune responses was performed at 2 weeks after last immunization. Determination of HCV NS3-or luciferase protein-expressing liver cells in vivo was performed in groups of immunized and nonimmunized mice. Presence of HCV NS3 protein expression was determined 72 hours after the targeted controlled force injection by western blot analysis.
Quantification of HCV NS3-specific CD8 + T cells by pentamer staining
The frequency of NS3-specific CD8 + T cells was analyzed by direct ex vivo staining of splenocytes using the NS3 GAVQNEVTL (H2-D b ) Pro5 pentamers (ProImmune, Oxford, UK) performed exactly as described previously. 23, 24 The following antibodies were used: antimouse CD16/32 "Fc block, " antimouse CD19-APC "clone 1D3" (BD Biosciences, San Jose, CA), and antimouse CD8-FITC "clone KT15" (ProImmune). A total of 150,000 events from each sample were acquired on a FACSCalibur or FACSVerse flow cytometer (BD Biosciences) and analyzed using the FlowJo V10.0.7 software (Tree Star, Ashland, OR).
Statistical analysis
All comparisons were performed using GraphPad InStat 3, Macintosh (version 3.0b, 2003; GraphPad Software, San Diego, CA) and Microsoft Excel 2011, Macintosh (version 14.3.9; Microsoft, Redmond, WA). Kinetic measurements were compared using the area under the curve (AUC, Excel). Parametrical data were compared using the analysis of variance and nonparametrical data with Mann-Whitney U-test. Frequencies were compared using Fisher's exact test. Official journal of the American Society of Gene & Cell Therapy
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